Biomimetic nanotherapeutics: Employing nanoghosts to fight melanoma

[Display omitted] Melanoma is a cancer of melanocytes present at the basal layer of the skin. Nanomedicine has armed us with competent platform to manage such fatal neoplastic diseases. Nevertheless, it suffers from numerous pitfalls such as rapid clearance and opsonization of surface-functionalized...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmaceutics and biopharmaceutics 2022-08, Vol.177, p.157-174
Hauptverfasser: Bagasariya, Deepkumar, Charankumar, Kondasingh, Shah, Saurabh, Famta, Paras, Khatri, Dharmendra Kumar, Singh Raghuvanshi, Rajeev, Bala Singh, Shashi, Srivastava, Saurabh
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 174
container_issue
container_start_page 157
container_title European journal of pharmaceutics and biopharmaceutics
container_volume 177
creator Bagasariya, Deepkumar
Charankumar, Kondasingh
Shah, Saurabh
Famta, Paras
Khatri, Dharmendra Kumar
Singh Raghuvanshi, Rajeev
Bala Singh, Shashi
Srivastava, Saurabh
description [Display omitted] Melanoma is a cancer of melanocytes present at the basal layer of the skin. Nanomedicine has armed us with competent platform to manage such fatal neoplastic diseases. Nevertheless, it suffers from numerous pitfalls such as rapid clearance and opsonization of surface-functionalized carriers, biocompatibility and idiopathic reactions which could be difficult to predict in the patient. Biomimetic approach, a novel step towards personalized medicine bridges these drawbacks by employing endogenous cell membranes to traverse physiological barriers. Camouflaged carriers coated with natural cell membranes possess unique characteristics such as high circulatory periods, and the absence of allogenic and xenogenic responses. Proteins residing on the cell membranes render a diverse range of utilities to the coated nanoparticles including natural efficiency to identify cellular targets, homologous targeting, reticuloendothelial system evasion, biocompatibility and reduced adverse and idiopathic effects. In the present article, we have focused on cell membrane camouflaged nanocarriers for melanoma management. We have discussed various types of biomimetic systems, their processing and coating approaches, and their characterization. We have also enumerated novel avenues in melanoma treatment and the combination of biomimetic systems with smart nanoparticulate systems with the potential to bring breakthroughs in the near future. Additionally, immunotherapy-based biomimetic systems to combat melanoma have been highlighted. Hurdles towards clinical translation and ways to overcome them have been explained in detail.
doi_str_mv 10.1016/j.ejpb.2022.06.014
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2685037794</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0939641122001370</els_id><sourcerecordid>2685037794</sourcerecordid><originalsourceid>FETCH-LOGICAL-c333t-6690a6ac0ee2de52d5367538d894a20eb58b80c05f8c3285c761e5723d18669d3</originalsourceid><addsrcrecordid>eNp9kDtPwzAQgC0EEqXwB5gysiSc7dhxEAtU5SFVYoHZcp1L6yipg-0i8e9JKTPT6R7f6e4j5JpCQYHK267AblwXDBgrQBZAyxMyo6riOS9LekpmUPM6lyWl5-Qixg4AykqoGVk8Oj-4AZOz2c7sfNpiMCPupzzeZcth7P23221-e5utjylmyWet22xTNmA_VQdzSc5a00e8-otz8vG0fF-85Ku359fFwyq3nPOUS1mDkcYCImtQsEZwWQmuGlWXhgGuhVorsCBaZTlTwlaSoqgYb6ia2IbPyc1x7xj85x5j0oOLFvvpCvT7qJlUAnhV1eU0yo6jNvgYA7Z6DG4w4VtT0AdjutMHY_pgTIPUk7EJuj9COD3x5TDoaB3uLDYuoE268e4__Ae31XRN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2685037794</pqid></control><display><type>article</type><title>Biomimetic nanotherapeutics: Employing nanoghosts to fight melanoma</title><source>Elsevier ScienceDirect Journals</source><creator>Bagasariya, Deepkumar ; Charankumar, Kondasingh ; Shah, Saurabh ; Famta, Paras ; Khatri, Dharmendra Kumar ; Singh Raghuvanshi, Rajeev ; Bala Singh, Shashi ; Srivastava, Saurabh</creator><creatorcontrib>Bagasariya, Deepkumar ; Charankumar, Kondasingh ; Shah, Saurabh ; Famta, Paras ; Khatri, Dharmendra Kumar ; Singh Raghuvanshi, Rajeev ; Bala Singh, Shashi ; Srivastava, Saurabh</creatorcontrib><description>[Display omitted] Melanoma is a cancer of melanocytes present at the basal layer of the skin. Nanomedicine has armed us with competent platform to manage such fatal neoplastic diseases. Nevertheless, it suffers from numerous pitfalls such as rapid clearance and opsonization of surface-functionalized carriers, biocompatibility and idiopathic reactions which could be difficult to predict in the patient. Biomimetic approach, a novel step towards personalized medicine bridges these drawbacks by employing endogenous cell membranes to traverse physiological barriers. Camouflaged carriers coated with natural cell membranes possess unique characteristics such as high circulatory periods, and the absence of allogenic and xenogenic responses. Proteins residing on the cell membranes render a diverse range of utilities to the coated nanoparticles including natural efficiency to identify cellular targets, homologous targeting, reticuloendothelial system evasion, biocompatibility and reduced adverse and idiopathic effects. In the present article, we have focused on cell membrane camouflaged nanocarriers for melanoma management. We have discussed various types of biomimetic systems, their processing and coating approaches, and their characterization. We have also enumerated novel avenues in melanoma treatment and the combination of biomimetic systems with smart nanoparticulate systems with the potential to bring breakthroughs in the near future. Additionally, immunotherapy-based biomimetic systems to combat melanoma have been highlighted. Hurdles towards clinical translation and ways to overcome them have been explained in detail.</description><identifier>ISSN: 0939-6411</identifier><identifier>EISSN: 1873-3441</identifier><identifier>DOI: 10.1016/j.ejpb.2022.06.014</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Biomimetic ; Homologous targeting ; Melanoma</subject><ispartof>European journal of pharmaceutics and biopharmaceutics, 2022-08, Vol.177, p.157-174</ispartof><rights>2022 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c333t-6690a6ac0ee2de52d5367538d894a20eb58b80c05f8c3285c761e5723d18669d3</citedby><cites>FETCH-LOGICAL-c333t-6690a6ac0ee2de52d5367538d894a20eb58b80c05f8c3285c761e5723d18669d3</cites><orcidid>0000-0003-0723-4363</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0939641122001370$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><creatorcontrib>Bagasariya, Deepkumar</creatorcontrib><creatorcontrib>Charankumar, Kondasingh</creatorcontrib><creatorcontrib>Shah, Saurabh</creatorcontrib><creatorcontrib>Famta, Paras</creatorcontrib><creatorcontrib>Khatri, Dharmendra Kumar</creatorcontrib><creatorcontrib>Singh Raghuvanshi, Rajeev</creatorcontrib><creatorcontrib>Bala Singh, Shashi</creatorcontrib><creatorcontrib>Srivastava, Saurabh</creatorcontrib><title>Biomimetic nanotherapeutics: Employing nanoghosts to fight melanoma</title><title>European journal of pharmaceutics and biopharmaceutics</title><description>[Display omitted] Melanoma is a cancer of melanocytes present at the basal layer of the skin. Nanomedicine has armed us with competent platform to manage such fatal neoplastic diseases. Nevertheless, it suffers from numerous pitfalls such as rapid clearance and opsonization of surface-functionalized carriers, biocompatibility and idiopathic reactions which could be difficult to predict in the patient. Biomimetic approach, a novel step towards personalized medicine bridges these drawbacks by employing endogenous cell membranes to traverse physiological barriers. Camouflaged carriers coated with natural cell membranes possess unique characteristics such as high circulatory periods, and the absence of allogenic and xenogenic responses. Proteins residing on the cell membranes render a diverse range of utilities to the coated nanoparticles including natural efficiency to identify cellular targets, homologous targeting, reticuloendothelial system evasion, biocompatibility and reduced adverse and idiopathic effects. In the present article, we have focused on cell membrane camouflaged nanocarriers for melanoma management. We have discussed various types of biomimetic systems, their processing and coating approaches, and their characterization. We have also enumerated novel avenues in melanoma treatment and the combination of biomimetic systems with smart nanoparticulate systems with the potential to bring breakthroughs in the near future. Additionally, immunotherapy-based biomimetic systems to combat melanoma have been highlighted. Hurdles towards clinical translation and ways to overcome them have been explained in detail.</description><subject>Biomimetic</subject><subject>Homologous targeting</subject><subject>Melanoma</subject><issn>0939-6411</issn><issn>1873-3441</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kDtPwzAQgC0EEqXwB5gysiSc7dhxEAtU5SFVYoHZcp1L6yipg-0i8e9JKTPT6R7f6e4j5JpCQYHK267AblwXDBgrQBZAyxMyo6riOS9LekpmUPM6lyWl5-Qixg4AykqoGVk8Oj-4AZOz2c7sfNpiMCPupzzeZcth7P23221-e5utjylmyWet22xTNmA_VQdzSc5a00e8-otz8vG0fF-85Ku359fFwyq3nPOUS1mDkcYCImtQsEZwWQmuGlWXhgGuhVorsCBaZTlTwlaSoqgYb6ia2IbPyc1x7xj85x5j0oOLFvvpCvT7qJlUAnhV1eU0yo6jNvgYA7Z6DG4w4VtT0AdjutMHY_pgTIPUk7EJuj9COD3x5TDoaB3uLDYuoE268e4__Ae31XRN</recordid><startdate>202208</startdate><enddate>202208</enddate><creator>Bagasariya, Deepkumar</creator><creator>Charankumar, Kondasingh</creator><creator>Shah, Saurabh</creator><creator>Famta, Paras</creator><creator>Khatri, Dharmendra Kumar</creator><creator>Singh Raghuvanshi, Rajeev</creator><creator>Bala Singh, Shashi</creator><creator>Srivastava, Saurabh</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0723-4363</orcidid></search><sort><creationdate>202208</creationdate><title>Biomimetic nanotherapeutics: Employing nanoghosts to fight melanoma</title><author>Bagasariya, Deepkumar ; Charankumar, Kondasingh ; Shah, Saurabh ; Famta, Paras ; Khatri, Dharmendra Kumar ; Singh Raghuvanshi, Rajeev ; Bala Singh, Shashi ; Srivastava, Saurabh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c333t-6690a6ac0ee2de52d5367538d894a20eb58b80c05f8c3285c761e5723d18669d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomimetic</topic><topic>Homologous targeting</topic><topic>Melanoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bagasariya, Deepkumar</creatorcontrib><creatorcontrib>Charankumar, Kondasingh</creatorcontrib><creatorcontrib>Shah, Saurabh</creatorcontrib><creatorcontrib>Famta, Paras</creatorcontrib><creatorcontrib>Khatri, Dharmendra Kumar</creatorcontrib><creatorcontrib>Singh Raghuvanshi, Rajeev</creatorcontrib><creatorcontrib>Bala Singh, Shashi</creatorcontrib><creatorcontrib>Srivastava, Saurabh</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bagasariya, Deepkumar</au><au>Charankumar, Kondasingh</au><au>Shah, Saurabh</au><au>Famta, Paras</au><au>Khatri, Dharmendra Kumar</au><au>Singh Raghuvanshi, Rajeev</au><au>Bala Singh, Shashi</au><au>Srivastava, Saurabh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomimetic nanotherapeutics: Employing nanoghosts to fight melanoma</atitle><jtitle>European journal of pharmaceutics and biopharmaceutics</jtitle><date>2022-08</date><risdate>2022</risdate><volume>177</volume><spage>157</spage><epage>174</epage><pages>157-174</pages><issn>0939-6411</issn><eissn>1873-3441</eissn><abstract>[Display omitted] Melanoma is a cancer of melanocytes present at the basal layer of the skin. Nanomedicine has armed us with competent platform to manage such fatal neoplastic diseases. Nevertheless, it suffers from numerous pitfalls such as rapid clearance and opsonization of surface-functionalized carriers, biocompatibility and idiopathic reactions which could be difficult to predict in the patient. Biomimetic approach, a novel step towards personalized medicine bridges these drawbacks by employing endogenous cell membranes to traverse physiological barriers. Camouflaged carriers coated with natural cell membranes possess unique characteristics such as high circulatory periods, and the absence of allogenic and xenogenic responses. Proteins residing on the cell membranes render a diverse range of utilities to the coated nanoparticles including natural efficiency to identify cellular targets, homologous targeting, reticuloendothelial system evasion, biocompatibility and reduced adverse and idiopathic effects. In the present article, we have focused on cell membrane camouflaged nanocarriers for melanoma management. We have discussed various types of biomimetic systems, their processing and coating approaches, and their characterization. We have also enumerated novel avenues in melanoma treatment and the combination of biomimetic systems with smart nanoparticulate systems with the potential to bring breakthroughs in the near future. Additionally, immunotherapy-based biomimetic systems to combat melanoma have been highlighted. Hurdles towards clinical translation and ways to overcome them have been explained in detail.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.ejpb.2022.06.014</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0003-0723-4363</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0939-6411
ispartof European journal of pharmaceutics and biopharmaceutics, 2022-08, Vol.177, p.157-174
issn 0939-6411
1873-3441
language eng
recordid cdi_proquest_miscellaneous_2685037794
source Elsevier ScienceDirect Journals
subjects Biomimetic
Homologous targeting
Melanoma
title Biomimetic nanotherapeutics: Employing nanoghosts to fight melanoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T17%3A17%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomimetic%20nanotherapeutics:%20Employing%20nanoghosts%20to%20fight%20melanoma&rft.jtitle=European%20journal%20of%20pharmaceutics%20and%20biopharmaceutics&rft.au=Bagasariya,%20Deepkumar&rft.date=2022-08&rft.volume=177&rft.spage=157&rft.epage=174&rft.pages=157-174&rft.issn=0939-6411&rft.eissn=1873-3441&rft_id=info:doi/10.1016/j.ejpb.2022.06.014&rft_dat=%3Cproquest_cross%3E2685037794%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2685037794&rft_id=info:pmid/&rft_els_id=S0939641122001370&rfr_iscdi=true